{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:15:41Z","timestamp":1788221741580,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds<\/jats:title>\n                    <jats:p>In Western countries, the standard perioperative treatment for resectable locally advanced esophagogastric junction adenocarcinoma (EGJ-AC) is 5-fluorouracil, oxaliplatin, and docetaxel (FLOT) therapy based on the results of the FLOT4 and ESOPEC trials. On the other hand, there was little evidence based on optimal perioperative treatment for resectable locally advanced EGJ-AC in Japan. Our previous report showed that neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy demonstrated modest efficacy for resectable locally advanced EGJ-AC. Therefore, we compared neoadjuvant DCF to FLOT therapy in terms of efficacy and safety in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the data of patients who received DCF or FLOT therapy for resectable EGJ-AC between 2015 and 2024 in our hospital. We assessed the R0 resection rate, histopathological response, disease-free survival (DFS), overall survival, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two patients in the DCF therapy group and 20 patients in the FLOT therapy group were analyzed. The patients\u2019 characteristics in the DCF group and FLOT group were as follows: median age, 63\/59\u00a0years; ECOG PS 0, 66%\/85%, respectively. The pCR rate was numerically higher in the FLOT group (20%) compared with the DCF group (3%) (p\u2009=\u20090.07). Similarly, the 1-year DFS rate was higher in the FLOT group (93%) than in the DCF group (68%) (p\u2009=\u20090.02), although this difference did not remain statistically significant after adjustment for baseline factors. Febrile neutropenia was significantly lower in the FLOT group (0%) than in the DCF group (12.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant FLOT therapy is well-tolerated and has comparable short-term efficacy to DCF therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10388-025-01168-x","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:53:58Z","timestamp":1762502038000},"page":"201-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Kazuhiro","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imazeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tairo","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Oguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"3","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram L, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterol. 2022;163(3):649-658.e2.","journal-title":"Gastroenterol"},{"issue":"6","key":"1168_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.canep.2012.07.009","volume":"36","author":"AT Gavin","year":"2012","unstructured":"Gavin AT, Francisci S, Foschi R, EUROCARE-4 Working Group, et al. Oesophageal cancer survival in Europe: a EUROCARE-4 study. Cancer Epidemiol. 2012;36(6):505\u201312.","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"1168_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/jama.1995.03530060048032","volume":"274","author":"WH Chow","year":"1995","unstructured":"Chow WH, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995;274(6):474\u20137.","journal-title":"JAMA"},{"issue":"11","key":"1168_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199903183401101","volume":"340","author":"J Lagergren","year":"1999","unstructured":"Lagergren J, Bergstr\u00f6m R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"1168_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/cncr.11568","volume":"98","author":"AH Wu","year":"2003","unstructured":"Wu AH, Tseng CC, Bernstein L, et al. Reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer. 2003;98(5):940\u20138.","journal-title":"Cancer"},{"issue":"2","key":"1168_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ajg.2012.387","volume":"108","author":"H Pohl","year":"2013","unstructured":"Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013;108(2):200\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1168_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s00535-019-01577-7","volume":"54","author":"K Matsuno","year":"2019","unstructured":"Matsuno K, Ishihara R, Ohmori M, et al. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma. J Gastroenterol. 2019;54(9):784\u201391.","journal-title":"J Gastroenterol"},{"issue":"7","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00535-017-1412-4","volume":"53","author":"S Koizumi","year":"2018","unstructured":"Koizumi S, Motoyama S, Iijima K. Is the incidence of esophageal adenocarcinoma increasing in Japan? Trends from the data of a hospitalbased registration system in Akita Prefecture. Jpn J Gastroenterol. 2018;53(7):827\u201333.","journal-title":"Jpn J Gastroenterol"},{"issue":"7","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","volume":"17","author":"JA Ajani","year":"2019","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Net. 2019;17(7):855\u201383.","journal-title":"J Natl Compr Canc Net"},{"issue":"2","key":"1168_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1634\/theoncologist.2014-0377","volume":"20","author":"N Ashraf","year":"2015","unstructured":"Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist. 2015;20(2):134\u201342.","journal-title":"Oncologist"},{"issue":"9","key":"1168_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomized controlled trial. Lancet Oncol. 2015;16(9):1090\u20138.","journal-title":"Lancet Oncol"},{"issue":"10184","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"4","key":"1168_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323\u201335.","journal-title":"N Engl J Med"},{"issue":"18","key":"1168_CR14","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810\u201320.","journal-title":"N Engl J Med"},{"issue":"12","key":"1168_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang H, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389\u201396.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1168_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296\u2013304.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1168_CR17","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Kim HD, Yook JD, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J Clin Oncol. 2024;42(25):2961\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1168_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"X Zhang","year":"2025","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(3):312\u20139.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1168_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R, et al. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer. 2024;27(2):366\u201374.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1168_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyad149","volume":"54","author":"R Kita","year":"2024","unstructured":"Kita R, Yanagimoto Y, Imazeki H, et al. Protocol digest of a randomized controlled adaptive phase II\/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan clinical oncology group study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol. 2024;54(2):206\u201311.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1168_CR21","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/annonc\/mdr465","volume":"23","author":"LE Ferri","year":"2012","unstructured":"Ferri LE, Ades S, Alcindor T, et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012;23(6):1512\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"1168_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1245\/s10434-014-3875-3","volume":"22","author":"M Sudarshan","year":"2015","unstructured":"Sudarshan M, Alcindor T, Ades S, et al. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Ann Surg Oncol. 2015;22(1):324\u201330.","journal-title":"Ann Surg Oncol"},{"issue":"10447","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366.","journal-title":"Lancet"},{"issue":"3","key":"1168_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s10388-024-01050-2","volume":"21","author":"T Hirose","year":"2024","unstructured":"Hirose T, Yamamoto S, Honma Y, et al. Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma. Esophagus. 2024;21(3):328\u201335.","journal-title":"Esophagus"},{"issue":"2","key":"1168_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1245\/s10434-011-1983-x","volume":"19","author":"Y Hosokawa","year":"2012","unstructured":"Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19(2):677\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1168_CR26","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/annonc\/annonc1482","volume":"35","author":"Y Yoshinami","year":"2024","unstructured":"Yoshinami Y, Yamamoto S, Shiraishi K, et al. Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable locally advanced esophageal squamous cell carcinoma. Ann Oncol. 2024;35(1):S162\u2013204. https:\/\/doi.org\/10.1016\/annonc\/annonc1482.","journal-title":"Ann Oncol"},{"key":"1168_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2503701","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/nejmoa2503701.","journal-title":"N Engl J Med"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-025-01168-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T21:05:12Z","timestamp":1769375112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-025-01168-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s10388-025-01168-x","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SY has received honoraria for lectures from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, and Taiho Pharmaceutical and Advisory Board for Ono Pharmaceutical and Bristol-Myers Squibb [outside of the submitted work]. YH has received research grants for Ono Pharmaceutical and Bristol Myers Squibb and honoraria for lectures from Ono Pharmaceutical and Bristol Myers Squibb, Novartis, MSD, Chugai phama, Eisai, Nutri, Bayer, Merck Biopharma, Eli Lilly, Teijin pharma, Taiho and Advisory Board for Jansen and Rakuten Medical Japan. [outside of the submitted work]. KK reports consulting fees from Bristol Myers Squibb and Merck Sharp and Dohme, BeiGene, Roche, AstraZeneca, and Bayer; honoraria from Ono Pharmaceuticals, Bristol Myers Squibb, and Taiho; research funding from Ono Pharmaceuticals, Bristol Myers Squibb, Merck Sharp and Dohme, BeiGene, Chugai, Shionogi, AstraZeneca, and Bayer for research subjects outside the submitted work. [outside of the submitted work]. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}